Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

bioMerieux and Shanghai Kehua Bio-engineering forges Chinese joint venture

BioMerieux : 01 February, 2008  (New Product)
Shanghai Kehua Bio-engineering and bioMerieux have created a Shanghai-based joint venture that will see bioMerieux transfer microplate immunoassay manufacturing currently located at its Boxtel site in the Netherlands.

bioMerieux will hold 60 percent of the capital in the joint venture. The alliance brings together Kehua’s strong manufacturing and development capabilities with bioMerieux’s expertise in immunoassays and infectious disease diagnostics.

The microplate range manufactured by the joint venture will be distributed by bioMerieux in the Europe, Middle East and Africa, Asia-Pacific (including China) and Latin America regions.

The two companies are also exploring opportunities for bioMerieux to distribute Kehua’s diagnostics through its extensive global network as part of a broader, long-term partnership.

“bioMerieux is a world famous company in the field of diagnostics, with extensive experience and strong global reputation. The cooperation will benefit both parties from brand image, sales network and complementary products pipeline,” stated Tang Wei Guo, board chairman of Kehua.

“Kehua is the market leader in Chinese diagnostics, with a proven track record of providing high quality, cost-efficient products,” stated Stephane Bancel, chief executive officer of bioMerieux. “Microplate immunoassays play an important role in public health. The alliance with Kehua will enable bioMerieux to provide this product line to our customers at a competitive price, thanks to an improved cost structure,” he added.

The transfer of manufacturing will be made progressively during 2008 and 2009 until the Dutch site’s closure.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo